(Q36569755)

15 August 2017

1 reference

title

Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases (English)

1 reference

15 August 2017

2

Pierre Youinou

1 reference

15 August 2017

Serge D Steinfeld

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

943-949

1 reference

Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Cellular and genetic mechanisms of self tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Peripheral deletion of self-reactive B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

CD22 regulates thymus-independent responses and the lifespan of B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

The role of CD22 and other inhibitory co-receptors in B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Epratuzumab in non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.943

21 January 2018

Identifiers

DOI

10.1517/14712598.6.9.943

1 reference

15 August 2017

1 reference